UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial
Reuben Benjamin(King's College London), Victoria Potter(King's College Hospital NHS Foundation Trust), Éolia Brissot(Inserm), Vicky Chu, Jen Lewis, Maria Almena-Carrasco(Servier (France)), Laarni Bonganay, Jackie Chappell, Matthieu Pannaux(Servier (France)), Mohamad Mohty(Sorbonne Université), Nitin Jain(Parul University), Marina Konopleva(Albert Einstein College of Medicine), Marcela V. Maus(Center for Cancer Research), Sandra Dupouy(Servier (France)), Svetlana Balandraud(Enterome (France)), Victoria Metaxa(Apple (Israel)), Piers Patten, Kirsty Cuthill, Elka Giemza, Koji Kato, Andrea Kühnl(King's College Hospital), Rose Ellard, Deborah Yallop(King's College Hospital NHS Foundation Trust), Najeem Folarin, Agnieszka Jóźwik(King's College Hospital NHS Foundation Trust), Floriane Boucaud(Servier (France)), Sylvain Fouliard(Servier (France)), Athos Gianella-Borradori(Servier (France)), Alan Dunlop(King's College Hospital), Matthew J. Frigault(Harvard University), Takanori Teshima(Hokkaido University Hospital), Helena Munro, Florence Binlich(Servier (France)), Nicolas Boissel(Inserm), Farzin Farzeneh, Gary Cheung, Antonio Pagliuca, Charlotte Graham(Broad Institute), Shireen Kassam, Alice Mason(King's College Hospital), Steven Devereux, M.Yu. Liskova(Servier (France)), Majid Kazmi, Lorraine Catt, Ghulam Mufti, Ibtissam Marchiq(AVL (France))
Cited by 139
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
|New England Journal of Medicine|2020|1.4k
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
|New England Journal of Medicine|2020|859